PFA Set to Capture Over 30% of U.S. Atrial Fibrillation Ablation Market Within 12 Months, Displacing RF and Cryo Technologies

Jun 11, 2024 22:15 CST Updated 22:15

Abbott

Provider of Health Diagnostic Products and Health Diagnostic Management Solutions

Johnson & Johnson

Medical Device R&D and Manufacturer

Medtronic

Medical Device Manufacturer

Since two PFA products received FDA approval at the end of last year and the beginning of this year, the use of PFA products to treat atrial fibrillation has become highly popular in U.S. hospitals, with doctors eager to use PFA for patient treatment.

In addition to the positive outlook from hospital doctors on PFA, the U.S. market also highly values PFA, which is expected to replace radiofrequency ablation and cryoablation in the near future. According to predictions by Industry and Wall Street, with its unique technical advantages, PFA will soon become the mainstream ablation technology for treating atrial fibrillation.

A survey of 25 electrophysiologists in the United States shows: In the next 12 months,The use of PFA will increase from 9% today to over 30%.Most doctors said that PFA would enable them to perform more heart surgeries.

In addition, the research shows that: Boston Scientific will be the biggest beneficiary of this electrophysiology revolution. Currently, Boston Scientific's market share in the electrophysiology ablation field is only 6%.Boston Scientific's market share will climb to over 16% in the next 12 months, and its sales in the United States will increase by $440 million.。

In the market, while some are pleased, others are worried. Abbott and Johnson & Johnson are among the most concerned companies in this field. Currently, the main products of Abbott and Johnson & Johnson in the electrophysiology ablation sector are based on radiofrequency ablation technology, which is leading to their traditional market share being replaced by the emerging PFA technology. Market forecastsJohnson & Johnson's market share will shrink by nearly 10 percentage points within 12 months.

Johnson & Johnson Market ShareFrontal Loss NotThe largest is Abbott. Due to Abbott's relatively late deployment in PFA technology, it is unable to quickly respond to the fierce competition from innovative PFA products like FARAPULSE and PulseSelect. Therefore, the market expects its market share to drop significantly. Moreover, the decline will be much greater than that of Johnson & Johnson.Johnson & Johnson's PFA product VARIPULSE has received CE and Japanese approval, with FDA approval expected in the second half of this year.VARIPULSE Launch.

Abbott's first PFA productVolt PFA has just received FDA approval for the IDE study. If the clinical study goes smoothly,Volt PFA will not be available on the market until 2027. By then, the entire electrophysiology market will have undergone tremendous changes, and Abbott could potentially shift from being a mainstream player to being categorized as "others." Despite this...Abbott believesVolt PFA has technical advantages that other PFA products do not possess, enabling it toAddress the limitations of existing PFA products.

Father of PFASteven MickelsenBoston Scientific is very confident in its FARAPULSE and believes that only PFA products with "contact force" functionality could potentially defeat FARAPULSE. Abbott's Volt PFA may not qualify.

For Medtronic, the electrophysiology ablation market in the next 12 months is a mix of opportunities and challenges. The positive aspect is thatPulseSElect is the first FDA-approved product and will also leveragePulseSElect and other technologies capture the radiofrequency ablation market. Concerns arise regarding its cryoablation.The Arctic Front series will be significantly impacted by PFA. According to statistical analysis.In the next 12 months, the market share of radiofrequency catheter ablation will drop from nearly 68% to less than 54% (a decline of over 20%).The share of cryoablation catheters is expected to drop from around 23% to below 16% (a decrease of over 30%). Medtronic'sPulseSThe increase in PFA sales will be offset by losses in the cryoablation market.Therefore, the market expects its performance in the electrophysiology ablation market over the next 12 months.Increase in market shareLess than 1%.

With the rise of PFA technology, the electrophysiology ablation market is undergoing tremendous changes. The rankings of the four major players in electrophysiology—Johnson & Johnson, Abbott, Medtronic, and Boston Scientific—are also shifting. Former underperformers could potentially rise to become leaders in the electrophysiology field. Two companies in China have already received approval for their PFA products. These two enterprises are not leaders in the electrophysiology sector in China. However, by being earlier to develop PFA products than companies like MicroPort or Mindray (Huitai), these emerging players may have the potential to disrupt the industry.Minimally Invasive,Mindray (Huitai)) and other veteran powerhouses, there is even a chance to defeat a strong opponent like Johnson & Johnson. It is expected that in this wave of technological revolution, China will be able to produce a contender to rival them.The innovative enterprise among the top four in electrophysiology.